Phenotype, Body Composition, and Prediction Equations (Indian Fatty Liver Index) for Non-Alcoholic Fatty Liver Disease in Non-Diabetic Asian Indians: A Case-Control Study

Surya Prakash Bhatt1,2,4, Anoop Misra1,3*, Priyanka Nigam1, Randeep Guleria2, M. A. Qadar Pasha4

1 Diabetic Foundation (India) and National Diabetes Obesity and Cholesterol Foundation (N-DOC), New Delhi, India, 2 Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi, India, 3 Fortis C-DOC Center of Excellence for Diabetes, Metabolic Diseases, and Endocrinology, B 16, Chirag Enclave, New Delhi, India, 4 Council of Scientific & Industrial Research-Institute of Genomics and Integrative Biology, Delhi, India

* anoopmisra@gmail.com

Abstract

Objective
In this study, we have attempted comparison of detailed body composition phenotype of Asian Indians with non-alcoholic fatty liver disease (NAFLD) vs. those without, in a case controlled manner. We also aim to analyse prediction equations for NAFLD for non-diabetic Asian Indians, and compare performance of these with published prediction equations researched from other populations.

Methods
In this case-control study, 162 cases and 173 age-and sex-matched controls were recruited. Clinical, anthropometric, metabolic, and body composition profiles, and liver ultrasound were done. Fasting insulin levels, value of homeostasis model assessment of insulin resistance (HOMA-IR), and serum high sensitive C-reactive protein (hs-CRP) levels were evaluated. Multivariate logistic and linear regression analyses were used to arrive at prediction equations for fatty liver [Indian fatty liver index (IFLI)].

Results
As compared to those without fatty liver, those with fatty liver exhibited the following; Excess dorsocervical fat (‘Buffalo hump’), skin tags, xanthelasma, ‘double chin’, arcus; excess total, abdominal and subcutaneous adiposity, and high blood pressure, blood glucose, measures of insulin resistance (fasting insulin and HOMA-IR values), lipids and hs-CRP levels. Two prediction equations were developed; Clinical [Indian Fatty Liver Index-Clinical (IFLI-C)]: 1(double chin) +15.5 (systolic blood pressure) +13.8 (buffalo hump); and IFLI-Clinical and Biochemical (CB): serum triglycerides+12 (insulin)+1(systolic blood pressure) +18
(buffalo hump). On ROC Curve analysis, IFLI performed better than all published prediction equations, except one.

**Conclusion**
Non-diabetic Asian Indians with NAFLD researched by us were overweight/obese, had excess abdominal and subcutaneous fat, multiple other phenotypic markers, had higher insulin resistance, glycemia, dyslipidemia and subclinical inflammation than those without. Prediction score developed by us for NAFLD; IFLI-C and IFLI-CB, should be useful for clinicians and researchers.

**Introduction**
Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of liver disorders characterized by accumulation of hepatic fat in absence of significant alcohol consumption (<20 gm/day) and other causes of liver diseases. It is most common cause of asymptomatic elevation of liver enzymes worldwide [1]. If fat accumulation continues, inflammation ensues in liver parenchyma, termed as non-alcoholic steatohepatitis (NASH), which has potential of progressing to cirrhosis.

Estimates based on imaging and autopsy studies suggest that about 20% to 30% of adults in the United States and other Western countries have NAFLD [2–4]. According to available sparse data in India, the prevalence of NAFLD ranges from 15–32% [5, 6]; variations in estimates are due to rural/urban habitat, socio-economic stratum, and varying dietary habits in different regions of country. Some data indicate that hepatic triglyceride content (estimated by proton magnetic resonance spectroscopy) of Asian Indians living in USA is more when compared to white Caucasians [7].

Several studies have suggested the associations of NAFLD with obesity, abdominal obesity, dysglycemia and other components of the metabolic syndrome [8]. Excess of body fat, mainly abdominal fat [9], is related to NAFLD [10]. Lin et al [11] reported that the waist circumference (WC) is better than body mass index (BMI) for predicting liver steatosis in Taiwanese subjects. Fallo et al [12] studied 86 hypertensive obese adults (48 NAFLD and 38 controls) and showed WC as predictor for NAFLD. Damaso et al [10] reported that the group of adolescents with NAFLD had significantly higher values of BMI, visceral and subcutaneous fat, insulin, and homoeostasis modal assessment for insulin resistance (HOMA-IR) in both genders, compared with control subjects living in Brazil.

It is now well established that Asian Indians have higher levels of body fat, more abdominal adipose tissue, less lean body mass (LBM) and higher magnitude of insulin resistance than American and European subjects [13, 14]. Some data suggest that fat deposition at ectopic places (nape of the neck, excess dorsocervical fat; ‘buffalo hump’; excess fat below chin; ‘double chin’, liver) correlates with the metabolic syndrome in Asian Indians [15]. Overall a phenotype of excess body fat, low muscle mass, and fat deposition, and ectopic fat deposition is characteristic for Asian Indians [16].

It is important to identify those at risk for development of NAFLD, so that appropriate investigations could be applied for evaluation and diagnosis and for management. An optimal prediction formula for NAFLD should include simple clinical parameters which could be used by clinicians. In this context, several prediction equations have been researched in other populations; North American [17], Finnish [18] and Italian [19] population.
While others and our group have investigated phenotype and body composition of diabetic and non-diabetic Asian Indians [20], detailed studies have not been carried out in persons with NAFLD. In this study, we have attempted comparison of phenotype of those with fatty liver with those without, in a case controlled manner. Further, we present prediction equations for Asian Indians, and compare performance of these prediction equations with published prediction equations from other populations.

**Methodology**

**Subjects**

In this case control study, we recruited a 335 overweight/obese (238 males and 97 females) subjects (BMI ≥23kg/m²), 162 (129 males and 33 females) with NAFLD (cases) and 173 (109 males and 64 females) without NAFLD (controls) at two clinical sites [Fortis Hospital and All India Institute of Medical Sciences, New Delhi, India] between May 2009 and October, 2014. The study was approved by the Institutional ethics committee at Fortis Hospital and All India Institute of Medical Sciences, New Delhi, India and written informed consent was obtained. NAFLD was defined by liver ultrasonography in those with alcohol intake of less than 20 gram/day [14]. Subjects with known type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), presence of other liver diseases (alcoholic liver disease, hepatitis virus infection, autoimmune hepatitis, primary biliary cirrhosis obstruction, drug-induced liver damage etc), severe organ damage in other organs, human immunodeficiency virus infection, pregnancy, lactation, or any pro-inflammatory state and patients on statins or fenofibrate were excluded from the study.

**Clinical and Anthropometric measurements**

Assessment of ‘buffalo hump’, ‘double chin’, acanthosis nigricans, skin tags or acrochordon and xanthelasma was done as described previously [15]. Blood pressure was measured by a standard mercury sphygmomanometer (Industrial Electronic and Allied Products, Pune, India) as previously [21]. Height, weight, WC, hip circumference (HC), mid arm circumference (MAC), mid thigh circumference (MTC), neck circumference (NC) and skinfold thickness at 6 sites (triceps, biceps, anterior axillary, suprailiac, subscapular and lateral thoracic) were measured according to standard protocols [22]. Subscapular: triceps skinfold thicknesses, and central (sum of subscapular and suprailiac): peripheral skinfold thicknesses (sum of biceps and triceps) were calculated.

**Biochemical analysis**

Fasting blood samples were analyzed for fasting blood glucose (FBG), and post-prandial (2 hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST), alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT) as previously [9]. Fasting insulin levels were measured using radioimmunoassay (RIA) kits (Immunotech, France) [5]. High sensitive (hs-CRP) levels were analyzed as previously described [23]. Overall, for all the parameters the intra and inter-assay percentage coefficient and coefficient of variations were <3.0%, 1.9% and <5%, respectively.

**Ultrasound imaging**

Presence of fat in liver was assessed with ultrasound using 3.5 MHz curvilinear probe (Siemens-G 60 S 2004, Germany). The definition of fatty liver was based on a comparative
assessment of image brightness relative to the kidneys, in line with previously reported diagnostic criteria [24]. Severity of fatty liver was classified according to the brightness compared to kidneys, blurring of gall bladder wall, of hepatic veins and of portal vein. The radiologists performing the ultrasound were unaware of the clinical and laboratory results.

Body composition

Percentage body fat (%BF), LBM and bone mineral density (BMD) were estimated by using whole body dual-energy X-ray absorptiometry (DEXA) scan (Lunar Prodigy Advanced Whole Body DEXA system, GE Medical Systems) as previously [5].

Definitions

Overweight and obesity defined as BMI ≥23–24.9 kg/m² and BMI ≥25 kg/m², respectively according to criteria for Asian Indians [22]. Similarly, WC cut-offs of ≥90 cm for males and ≥80 cm for females were considered an indicator of abdominal obesity [25]. FBG ≥100 mg/dl, serum TG ≥150 mg/dl (or on lipid lowering drugs), blood pressure >130/85 mmHg (or on antihypertensive therapy) and HDL-C; males ≤40 mg/dl, and females ≤50 mg/dl [26] were defined as abnormal. Insulin resistance was measured by two surrogate measures: fasting hyperinsulinemia and Homoeostasis Model Assessment of insulin resistance (HOMA-IR). The value of HOMA-IR was calculated as = fasting insulin (μU/ml) × fasting glucose (mmol/l)/22.5 [27]. Finally, hs-CRP level >1 mg/L was defined as high [22].

Statistical Analysis

Data were entered in an Excel spreadsheet (Microsoft Corp, Washington, USA). The distribution of clinical, biochemical, anthropometry and body composition parameters was confirmed for approximate normality. We used mean and standard deviation to summarize the variables. The differences in biochemical anthropometry and body composition parameters in cases and controls were compared using the Student's t-test. Difference between proportions was tested using Chi-square test. Bivariate logistic regression was performed to identify significant predictors of NAFLD. After adjusting for age, sex, TG, TC, HDL-C, LDL-C, WC, FBG, ALT, AST, ALK, fasting insulin, HOMA and % BF; multivariable logistic regression was carried out to identify the independent risk factor(s) and to estimate odds ratio (OR) and 95% confidence interval. For all above, a p value of <0.05 was considered as statistically significant.

We calculated the area under curve (AUC) for the receiver operating characteristic (ROC) for developing prediction equation for Asian Indians, henceforth termed as Indian Fatty Liver Index (IFLI). The performance of IFLI was compared with previously researched prediction equations in other populations as given below;

1. Fatty Liver Index (FLI) includes BMI, γ-GGT, TG, and WC [17]. FLI = (e0.953*logy (TG)+0.139 X BMI+0.718 X loge (GGT)+0.053X WC -15.745) / (1 + e 0.953 X loge (TG) + 0.139 X BMI + 0.718 X loge (GGT) + 0.053 X WC—15.745) X 100.

2. Lipid Accumulation Product (LAP) was calculated by expressing waist enlargement as the measured WC that exceeded a sex-specific minimum WC value and then multiplying it by fasting TG levels [18]. LAP for men = WC [cm]—65) × TG [mmol/L], and for women = WC [cm]—58) × TG [mmol/L].

3. NAFLD Liver Fat Score (LFS) includes AST/ALT ratio, T2DM, fasting AST level, fasting insulin level, and metabolic syndrome [19]. NAFLD liver fat score = -2.89+1.18 X metabolic
syndrome (yes = 1/no = 0) + 0.45 X type 2 diabetes (yes = 2/no = 0) +0.15X fasting serum insulin (mU/L) + 0.04 X fasting AST (U/L)-0.94 XAST/ALT.

4. Liver Fat (%) includes metabolic syndrome, T2DM, fasting insulin, AST and AST/ALT ratio [19]. Liver Fat (%) = 10 (-0.805+0.282 X metabolic syndrome (yes = 1/no = 0) +0.078 X type 2 diabetes (yes = 2/no = 0)+ 0.525 X LOG (Fasting-insulin (mU/L)+ 0.521 X LOG (fasting AST (U/L)- 0.454 X LOG (AST/ALT))

Sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR), and corresponding 95% CIs were calculated for all equations for comparison. The non-invasive NAFLD measurement with the best performance (in terms of AUC for ROC) was then evaluated.

Results

Demographic, clinical, anthropometric, biochemical and body composition profiles

Mean age of cases and controls) was similar. Buffalo hump, skin tags, xanthelasma, double chin, arcus, systolic blood pressure, diastolic blood pressure, BMI, WC, hip circumference (HC), waist hip ratio (WHR), mid thigh circumference (MTC), value of skinfolds; subscapular, suprailiac, lateral thoracic, thigh and central skin folds were significantly higher in cases as compared to controls (Table 1, Fig 1).

The levels of fasting blood glucose, serum TG, TC, LDL-C, VLDL, ALT, GGT, fasting insulin, HOMA-IR and hs-CRP were significantly higher in cases as compared to controls (Table 2). The intra and inter assay percentage coefficient variables were 2.30% and 1.92% for insulin and 2.03% and 1.56% for hs-CRP, respectively.

| Variables                        | With NAFLD       | Without NAFLD   | p value |
|----------------------------------|------------------|-----------------|---------|
| Age (yrs)                        | 38.2±7.0         | 37.1±6.9        | 0.08    |
| Sex* Male                        | 129 (79.6)       | 109 (63.0)      | 0.001   |
| Female                           | 33 (20.3)        | 64 (36.9)       |         |
| Body mass index (kg/m²)          | 26.1±3.2         | 26.8±3.2        | 0.006   |
| Waist circumference (cm)         | 94.5±4.4         | 89.8±9.1        | 0.001   |
| Hip circumference (cm)           | 96.9±7.2         | 94.5±8.2        | 0.005   |
| Waist-hip ratio                  | 0.96±0.1         | 0.9±0.1         | 0.004   |
| MTC (cm)                         | 55.8±7.7         | 53.4±8.4        | 0.008   |
| MAC (cm)                         | 28.1±3.3         | 27.4±5.7        | 0.1     |
| Neck circumference (cm)          | 34.7 ± 4.2       | 33.9 ± 3.1      | 0.1     |
| Acanthosis nigricans*            | 35 (21.60)       | 28 (16.1)       | 0.1     |
| Buffalo hump*                    | 47 (29.01)       | 20 (11.5)       | 0.001   |
| Double chin*                     | 82 (50.6)        | 51 (29.4)       | 0.001   |
| Skin tags*                       | 76 (47.20)       | 56 (32.3)       | 0.004   |
| Xanthelasma*                     | 15 (9.26)        | 4 (2.31)        | 0.005   |
| Systolic blood pressure (mmHg)   | 125.0±11.8       | 119.3±11.0      | 0.001   |
| Diastolic blood pressure (mmHg)  | 80.2±8.6         | 77.4±8.6        | 0.003   |

*All values are given as the number (%). P value <0.05 is statistically significant. Values are given as the mean ±standard deviation. MTC, mid thigh circumference; MAC, mid arm circumference.

doi:10.1371/journal.pone.0142260.t001
Body composition by Dual Energy X-ray Absorptiometry profiles were presented in Fig 2 and S1 Table. The values of right leg lean mass, right leg total mass, trunk fat percentage, trunk fat, total trunk mass, %BF and BF were significantly higher in cases as compared to controls, whereas % LBM and LBM were higher in controls.

Univariate and step-wise logistic regression model

Using Univariate logistic regression model (Table 3), significant risk factors associated with the development of NAFLD were; double chin, buffalo hump, skin tag, xanthelasma, systolic blood pressure, WC, BMI, %BF, TG, fasting insulin, HOMA-IR and Hs-CRP. Using a step-wise logistic regression model as shown in Table 4, the significant factors associated with the development of NAFLD were double chin [2.2(1.21–7.0), p = 0.02], buffalo hump [2.94 (1.22–4.13), p = 0.01], systolic blood pressure [3.88 (0.97–10.4), p = 0.05], TG [2.33 (1.18–4.60), p = 0.01] and fasting Insulin [2.75 (1.38–5.50), p = 0.004].

Prediction Models

1. Using Clinical variables (IFLI-C)

Three clinical variables found to be significant in the logistic model were used to calculate
the prediction score for NAFLD. The simplest equation for estimation of clinical parameters is: 1(double chin) +15.5(systolic blood pressure) +13.8(buffalo hump) (maximum score = 28.7, minimum score = 0). Systolic blood pressure: 1: (>120/80 mmHg); 0: otherwise. Using a ROC analysis (Fig 3) a score cut-off of ≥1 ensured the best balance between sensitivity and specificity. The sensitivity, specificity and ROC area under the curve (95% CI) were 64.81%, 61.85%, and 65.0 (59.0–70.67), respectively. The probability of subject having NAFLD was more if score was ≥1 with positive likelihood ratio = 1.67 and negative likelihood ratio = 0.58.

2. Using Clinical and Biochemical variable (IFLI-CB)

Three clinical variables found to be significant in the logistic model were used to calculate the prediction score for NAFLD. The simplest equation for estimation of clinical and biochemical variables are: serum triglycerides +12(insulin) +16(systolic blood pressure) +18(buffalo hump) (maximum score = 47, minimum score = 0). Serum triglycerides: 1: (>150 mg/dL); 0: otherwise; fasting Insulin: 1: (>2.7 μU/ml); 0: otherwise; systolic blood pressure: 1: (>120/80 mmHg); 0: otherwise. Using a ROC analysis (Fig 3) a score cut-off of ≥12 ensured the best balance between sensitivity and specificity. The sensitivity, specificity and ROC area under the curve (95% CI) were 64.81%, 66.81%, and 71.9 (65.09–78.1). The probability of subject having NAFLD was more if score was ≥28 (positive likelihood ratio = 2.09, negative likelihood ratio = 0.51).

Comparisons of IFLI-C and IFLI-CB with Previously Published Equations (Table 5)

Importantly, ROC performances of IFLI-C (65.0%) and IFLI-CB (71.9%) were similar to NAFLD LFS but better than the FLI, LAP and Liver Fat (%).
Discussion

This detailed phenotype analysis of patients with NAFLD shows adverse body composition features; high body fat, truncal fat, truncal subcutaneous fat, low lean mass, and ectopic fat deposition; excess fat deposition below chin (‘double chin’) and over the nape of the neck (‘buffalo hump’). Moreover, we present two prediction equations for NAFLD, one based on clinical parameters alone (IFLI-C), and other, a combination of clinical and biochemical parameters (IFLI-CB).

Overall, previous studies have shown that Asian Indians have more fat in various abdominal fat depots. In a comparative study of Asian Indians vs. white Caucasians in USA; for similar value of BMI, migrant Asian Indians had significantly greater total abdominal fat and intra-abdominal adipose tissue (IAAT) [28]. Some investigators have reported that truncal subcutaneous adipose tissue (SCAT; measured by subscapular and supra-iliac skinfolds and by magnetic resonance imaging) is thicker in South Asians than in White Caucasians [29, 30]. Recently, we have also shown that pancreatic volume (surrogate marker of pancreatic fat) and liver span (surrogate marker of liver fat) correlate strongly to diabetes in non-obese individuals [31]. Thicker truncal subcutaneous fat, as shown by skinfolds, and more truncal fat, signifies
overall increased truncal and abdominal adiposity in persons with NAFLD in the current study. These increase fat depots, consisting mostly of metabolically dysfunctional adipocytes [32], generate increased amount of non-esterified fatty acids contributing significantly to fatty liver. It is important to note low lean mass in those with NAFLD, which may also of significance to glucose metabolism, and has been shown to have genetic basis in Asian Indians [33].

'Buffalo hump' and 'double chin', both signifying excess fat deposition at unusual sites, have been described by us as phenotypic markers closely correlating with metabolic syndrome in Asian Indians [15]. Incidentally, 'buffalo hump' is also present in HIV-associated lipodystrophy after prolonged use of protease inhibitors [34], and is associated with overall state of insulin resistance. Further, 'double chin' is commonly associated with diabetes in patients with partial lipodystrophies [34]. In the present study, both phenotypic markers were associated with NAFLD. Of significant note, both these signs could easily be detected on simple visual examination.

Interestingly, there are differences in the diagnostic prediction of different non-invasive scores, which may be accounted by sample of different populations studies and use of

Table 3. Univariate logistic regression analysis.

| Variable                | Unadjusted OR (95% CI) | p value |
|-------------------------|------------------------|---------|
| % Body fat              | 4.82 (2.4–9.71)        | 0.0001  |
| Xanthelasma             | 4.31 (1.40–13.3)       | 0.004   |
| Body mass index         | 3.33 (0.86–12.9)       | 0.05    |
| Buffalo hump            | 3.13 (1.76–5.57)       | 0.0001  |
| Fasting Insulin         | 3.03 (1.74–5.3)        | 0.001   |
| hs-CRP                  | 2.97 (1.08–8.2)        | 0.007   |
| Serum triglycerides     | 2.68 (1.7–4.31)        | 0.001   |
| Double chin             | 2.45 (1.56–3.84)       | 0.0001  |
| Systolic blood pressure | 2.0 (0.94–4.20)        | 0.05    |
| Skin tag                | 1.87 (1.19–2.91)       | 0.005   |
| Waist circumference     | 1.60 (1.02–2.50)       | 0.03    |
| HOMA-IR                 | 1.54 (0.91–2.64)       | 0.05    |

Hs-CRP, high sensitive C-reactive protein. HOMA-IR, homeostasis modal assessment for insulin resistance.

doi:10.1371/journal.pone.0142260.t003

Table 4. Adjusted odds ratios (ORs) and 95% confidence intervals (CI) calculated using multivariate logistic regression analyses.

| Variable                | Adjusted OR (95% CI) | p value |
|-------------------------|----------------------|---------|
| Clinical                |                      |         |
| Systolic blood pressure | 3.88 (0.97–10.4)     | 0.05    |
| Buffalo hump            | 2.94 (1.22–4.13)     | 0.01    |
| Double chin             | 2.2 (1.21–7.0)       | 0.02    |
| Biochemical             |                      |         |
| Fasting Insulin         | 2.75 (1.38–5.50)     | 0.004   |
| Serum triglycerides     | 2.33 (1.18–4.60)     | 0.01    |

Adjusted ORs were adjusted taking in consideration HOMA, hs CRP, diastolic blood pressure, weight, BMI, hip circumference, mid thigh circumference and total cholesterol.

doi:10.1371/journal.pone.0142260.t004
variegated phenotypic and biochemical measurements. Overall, assessment of phenotype done by us has been extensive, and includes conventional and novel signs (acanthosis nigricans, "buffalo hump"/"double chin") based on previous studies done by others and by us. Many of these signs/markers have not been taken in account by other investigators while researching prediction equations. Further, some prediction equations include subjects with T2DM, which we have strictly excluded them, because many other variables in patients with T2DM may confound the prediction. These include changes the weight following diet and exercise; inclusion of drugs such as metformin and thiazolidinediones and vitamin E, all of which may have effect on liver fat.

Fig 3. Area under curve (AUC) and 95% confidence interval (CI) for Indian Fatty Liver Index (IFLI), Fatty Liver Index (FLI), Lipid Accumulation Product (LAP), Liver Fat (LF) (%) and NAFLD Fat Score (NFS). A, IFLI-clinical; B, FLI; C, IFLI-clinical and biochemical; D, LAP; E, % LF and F, NFS.

doi:10.1371/journal.pone.0142260.g003
Table 5. Comparison of Indian Fatty Liver Index, Fatty Liver Index, Lipid Accumulation Index, Liver Fat (%) and NAFLD Liver Fat Score prediction scores.

| NAFLD Prediction score | AUC    | 95%CI               | Cut off | Sensitivity | Specificity | LR+ | LR- |
|------------------------|--------|---------------------|---------|-------------|-------------|-----|-----|
| Indian Fatty Liver Index | 65     | 59.1–70.67          | ≥1.0    | 64.2        | 61.85       | 1.67| 0.58|
| CB                     | 71.9   | 65.09–78.1          | ≥28     | 64.29       | 66.81       | 2.09| 0.51|
| Fatty Liver Index¹     | 63.2   | 47.8–64.4           | ≥99.25  | 57.28       | 57.65       | 1.35| 0.74|
| Lipid Accumulation Product² | 61.4   | 58.3–70.2           | ≥228.6  | 60.38       | 60.23       | 1.52| 0.66|
| Liver Fat (%)³         | 62.4   | 55.1–69.8           | ≥858.13 | 60.71       | 60.18       | 1.52| 0.66|
| NAFLD Liver Fat Score³ | 62.4   | 57.9–72.3           | 0.714   | 62.5        | 62.83       | 1.71| 0.67|

All p values are <0.001. CB, Clinical and biochemical; AUC, area under curve; LR, likelihood ratio (+, positive; -, negative).

¹n, 216 with and 280 without suspected liver disease; fatty liver was diagnosed by ultrasonography (17).
²n, 588; definition of fatty liver was based on liver ultrasonography (18).
³n, 359 non-diabetic, 111 type 2 diabetes; liver fat content was measured using proton magnetic resonance spectroscopy (19).

doi:10.1371/journal.pone.0142260.t005

It has been argued that other methods; magnetic resonance spectroscopy and liver biopsy are better tools for defining NAFLD, and could be considered as “gold standard”. Conversely, ultrasonography is by far the most common method of diagnosing NAFLD in clinical practice and has a fair sensitivity (87%) and specificity (94%) in detecting hepatic steatosis [35]. In a recent meta-analysis, forty-nine (4720 participants) studies regarding ultrasonography for diagnosis of fatty liver were included. Interestingly, the overall sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of ultrasound for the detection of moderate-severe fatty liver, compared to histology (gold standard), were 84.8% (95% confidence interval: 79.5–88.9), 93.6% (87.2–97.0), 13.3 (6.4–27.6), and 0.16 (0.12–0.22), respectively. Further, the area under the summary receiving operating characteristics curve was 0.93 (0.91–0.95). Overall, sensitivity and specificity of ultrasound was similar to that of other imaging techniques (i.e., computed tomography or magnetic resonance imaging) [36]. In summary, ultrasonography for liver fat is simple to perform, non-invasive, cost-effective and does not entail any radiation hazard, and could also be used in the epidemiological studies. Hence, although not “gold standard”, this method of investigation provides reasonable alternative to more expensive and difficult-to-perform diagnostic methods of NAFLD.

Two investigators have previously formulated prediction equations based on liver ultrasound estimated liver fat [17, 19]. In first study (prediction equation, FLI), 216 subjects with and 280 without NAFLD were studied [17], while in second study (prediction equation, LAP) 588 Italian adults were studied [18]. The performances of both the prediction equations on ROC curve analysis were inferior than IFLI-C and IFLI-CB presented by us. NAFLD Liver Fat score was developed using most robust estimation of liver fat using magnetic resonance spectroscopy in 470 Finnish subjects (non-diabetic and patients with T2DM) [19]. This score, however, performed better than IFLI on ROC curve analysis.

**Conclusion**

Non-diabetic Asian Indians with NAFLD sampled by us, as compared to those without NAFLD, had adipose and insulin resistant phenotype. We also present prediction score for NAFLD; IFLI-C and IFLI-CB, which should be useful for clinicians and researchers.
Supporting Information

S1 Table. Body composition by Dual Energy X-ray Absorptiometry. (DOC)

Acknowledgments

The authors acknowledge the contribution of Mr Kirti Pratap who performed many of the biochemical investigations. Finally, the cooperation of the subjects who took part in the study is greatly appreciated.

Author Contributions

Conceived and designed the experiments: AM. Performed the experiments: SPB PN. Analyzed the data: SPB. Contributed reagents/materials/analysis tools: SPB AM RG MAQP. Wrote the paper: SPB AM.

References

1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003. 37(4): p. 917–23. PMID: 12668987
2. Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig. 2015; 6(3): 309–316. doi: 10.1111/jdi.12290 PMID: 25969716
3. Liu SH, Lazo M, Koteish A, Kao WH, Shih MH, Bonekamp S, et al. Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III. J Gastroenterol. 2013; 48(10):1151–9. doi:10.1007/s00535-012-0715-8 PMID: 23188092
4. Lazo M, Hemaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1):38–45. doi: 10.1093/aje/kws448 PMID: 23703888
5. Bajaj S, Nigam P, Luthra A, Pandey RM, Kondal D, Bhatt SP et al. A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease. Indian J Med Res 2009; 129: 285–292. PMID: 19491421
6. Mohan V, Farooq S, Deepa M, Ravikumar R, Plichumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009; 84(1):84–91. doi: 10.1016/j.diabres.2008.11.039 PMID: 19168251
7. Misra A, Khurana K. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord. 2009; 7(6):497–514. doi: 10.1089/met.2009.0024 PMID: 19900153
8. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917–923. PMID: 12668987
9. Santos RR, Cotrim HP. Relevance of anthropometric measurements in the evaluation of patients with non-alcoholic fatty liver disease. Rev Bras Nutr Clin 2006; 21: 229–232.
10. Damaso AR, Do Prado WL, De Piano A, Tock L, Caranti DA, Lofrano MC, et al.: Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis 2008, 40:132–139. PMID: 18082476
11. Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC: Risk factors for liver steatosis in obese children and adolescents. Pediatr Neonatal 2010; 51(3):149–154. doi: 10.1016/S1875-9572(10)60028-9 PMID: 20675238
12. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G et al., Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension, Nutri, Metab and Cardio Dis, 2009, 19 (9), 646–653.
13. Misra A, Ramchandran A, Jayawardena R, Shrivastava U, Shehalatha C. Diabetes in South Asians. Diabet Med. 2014; 31(10):1153–62. doi: 10.1111/dmea.12540 PMID: 24975549
14. Banerji MA, Faridi N, Alturi R, Chakraborty RL, Lebovitz HE. Body composition, visceral fat, leptin and insulin resistance in Asian Indian men. J Clin Endocrinol Metab, 1999, 84:137–144. PMID: 9920074
15. Misra A, Jaiswal A, Shakti D, Wasir J, Vikram NK, Pandey RM, et al. Novel phenotypic markers and screening score for the metabolic syndrome in adult Asian Indians. Diabetes Res Clin Pract. 2008; 79 (2), e1–5: PMID:17881078

16. Misra A, Shrividstava U. Obesity and Dyslipidemia in South Asians. Nutrients 2013, 5(7), 2708–2733 doi:10.3390/nu5072708 PMID:23863826

17. Bedogni G, Bellantani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006, 6:33. PMID: 17081293

18. Bedogni G, Kahn HS, Bellentani S, Tiribelli C: A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010, 10:98 doi:10.1186/1471-230X-10-98 PMID: 20738444

19. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al: Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137:865–872. doi:10.1053/j.gastro.2009.06.005 PMID: 19524579

20. Joseph L, Wasir JS, Misra A, Vikram NK, Goel K, Pandey RM et al. Appropriate values of adiposity and lean body mass indices to detect cardiovascular risk factors in Asian Indians. Diabetes Technol Ther. 2011; 13(9):899–906. doi:10.1089/dia.2011.0014 PMID: 21714683

21. Madhavan M, Pandey RM, Misra A, Vikram NK, Dhingra V, Luthra K, et al. Centile values for serum lipids and blood pressure for Asian Indian adolescents. Lipids Health Dis 2005, 29; 4:20. PMID: 16194275

22. Dudeja V, Misra A, Pandey RM, Devina G, Kumar G, Vikram NK. BMI does not accurately predict overweight in Asian Indians in Northern India. Br J Nutr 2001; 86: 105–112. PMID: 11432771

23. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499–511. PMID: 12551878

24. Tam KM, Wu JS. Ultrasonographic diagnosis of fatty liver. Taiwan Yi Xue Hui Za Zhi. 1986; 85(1):45–53. PMID: 3519848

25. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009; 57: 163–70. PMID: 19582986

26. Lambert M, Paradis G, O’Loughlin J, Delvin EE, Hanley JA, Levy E. Insulin resistance syndrome in a representative sample of children and adolescents from Quebec, Canada. Int J Obes Relat Metab Disord 2004; 28: 833–841. PMID: 15170466

27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419. PMID: 3899825

28. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001; 86(11):5366–71. PMID: 11701707

29. Chowdhury B, Lantz H, Sjostrom L. Computed tomography-determined body composition in relation to cardiovascular risk factors in Indian and matched Swedish males. Metabolism 1996; 45: 634–644. PMID: 8622609

30. Peters J, Ulijaszek SJ. Population and sex differences in arm circumference and skinfold thicknesses among Indo-Pakistani children living in the East Midlands of Britain. Ann Hum Biol 1992; 19: 17–22. PMID: 1734819

31. Misra A, Anoop S, Gulati S, Mani K, Bhatt S P, Pandey RM. Body fat patterning, Hepatic fat and Pancreatic Volume of Non-obese Asian Indians with Type 2 Diabetes in North India: A Case-control Study. PLoS One (in press).

32. Chandalia M1, Davila H, Pan W, Szusztkiewicz M, Tuvendorf D, Livington EH, et al. Adipose tissue dysfunction in humans: a potential role for the transmembrane protein ENPP1. J Clin Endocrinol Metab. 2012; 97(12):4663–72. doi: 10.1210/jc.2012-2018 PMID: 23012391

33. Bhatt SP, Nigam P, Misra A, Guleria R, Luthra K, Jain SK, et al. Association of the Myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in North India. PLoS One. 2012; 7(8):e40977. doi: 10.1371/journal.pone.0040977 PMID: 22916099

34. Garg A, Misra A. Lipodystrophies and diabetes. In: International Textbook of Diabetes Mellitus. Defronzo RA (Eds). John Wiley. Sussex, London, Toronto, New York. 2004.

35. Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic
patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 2002; 34:516–22
PMID: 12236486

36. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E et al. Diagnostic Accuracy and Reliability of Ultrasonography for the Detection of Fatty Liver: A Meta-Analysis. Hepatology. 2011; 54(3): 1082–1090 doi: 10.1002/hep.24452 PMID: 21618575